Other equities research analysts have also recently issued research reports about the company. Oddo Securities set a €13.00 ($15.48) target price on MediGene AG and gave the company a buy rating in a report on Saturday, May 20th. Baader Bank set a €19.00 ($22.62) target price on MediGene AG and gave the company a buy rating in a report on Saturday, May 20th.
Shares of MediGene AG (ETR:MDG1) traded down 2.17% during trading on Monday, reaching €13.52. The company had a trading volume of 95,110 shares. The firm’s market capitalization is €299.04 million. The firm’s 50 day moving average price is €10.13 and its 200 day moving average price is €11.22. MediGene AG has a 12 month low of €6.65 and a 12 month high of €15.19.
WARNING: This piece was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://sportsperspectives.com/2017/09/05/medigene-ag-mdg1-given-a-13-00-price-target-at-independent-research-gmbh.html.
MediGene AG Company Profile
Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase.
Receive News & Ratings for MediGene AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediGene AG and related companies with MarketBeat.com's FREE daily email newsletter.